ARGX vs ZBH
argenx SE vs Zimmer Biomet — AI-powered side-by-side comparison
| Metric | ARGX | ZBH |
|---|
| AI Score |
69
|
69
|
| Price |
$864.40
|
$97.22
|
| P/E Ratio |
31.34×
|
23.54×
|
| ROE |
17.6%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
69.9%
|
| Debt / Equity |
0.01×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
47.9
|
63.1
|
| Beta |
-0.022
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for ARGX versus ZBH.
The committee scores are tied.
ARGX and ZBH both score 69/100.
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical